EFFICACY OF HEAT-INACTIVATED HEPATITIS B VACCINE IN HAEMODIALYSIS PATIENTS AND STAFF: Double-blind Placebo-controlled Trial
The efficacy of a heat-inactivated hepatitis B vaccine, 3 μg of surface antigen (HBsAg), given at 0, 1, 2, and 5 months, was evaluated in 401 haemodialysis patients in 18 centres by a placebo-controlled, double-blind, randomised trial. The attack-rate of hepatitis B virus (HBV) infections in the con...
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) 1983-12, Vol.322 (8363), p.1323-1328 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1328 |
|---|---|
| container_issue | 8363 |
| container_start_page | 1323 |
| container_title | The Lancet (British edition) |
| container_volume | 322 |
| creator | Desmyter, J. De Groote, G. Colaert, J. Reynders, M. Reerink-Brongers, E.E. Dees, P.J. Lelie, P.N. Reesink, H.W. |
| description | The efficacy of a heat-inactivated hepatitis B vaccine, 3 μg of surface antigen (HBsAg), given at 0, 1, 2, and 5 months, was evaluated in 401 haemodialysis patients in 18 centres by a placebo-controlled, double-blind, randomised trial. The attack-rate of hepatitis B virus (HBV) infections in the control group was 18% over 435 days. The protective efficacy rate of the vaccine was 78% against all HBV infections in the entire study (p= 0·00016), and 94% against HBsAg-positive hepatitis more than 3 months after day 0. Those patients in whom HBV developed showed no evidence of vaccine-acquired anti-HBs. Among 152 similarly randomised staff members receiving three monthly injections, all 5 HBsAg-positive infections occurred in the placebo group (p=0·022). The vaccine induced anti-HBs in 88% of the patients and 100% of the staff. Immediately after the fourth injection, anti-HBs levels were as high in responding patients as in staff. There were no serious side effects. In the four-dose schedule the vaccine provides dialysis patients with protection of the same order as that given by other hepatitis B vaccines to normal subjects. |
| doi_str_mv | 10.1016/S0140-6736(83)91089-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pasca</sourceid><recordid>TN_cdi_proquest_journals_2138571455</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673683910899</els_id><sourcerecordid>2138571455</sourcerecordid><originalsourceid>FETCH-LOGICAL-e181t-fa9fa1d8dd84a323f3e09c00b34105c22de5e626e57c8c0a1ee3ecea470698353</originalsourceid><addsrcrecordid>eNo9kcFq3DAQhkVpoNukj1AQJIf2oESyZFvKpaheO2vYeANWQ3MSWnkMDo6dyruFkJePNwk5Dcx8zPzMh9B3Rs8ZZclFTZmgJEl58kPyn4pRqYj6hBZMpILEIv37GS0-kC_o6zTdU0pFQuMFes6Losx0doc3BV7l2pCy0pkpb7XJl3PjRpvSlDX-jW91lpVVjssKr3R-vVmWen1Xz6MDklemxrpa4troorjEy3G_7YFs-25o8E3vPGxH4sdhF8a-hwab0Ln-BB21rp_g23s9Rn-K3GQrst5czZnWBJhkO9I61TrWyKaRwvGItxyo8pRuuWA09lHUQAxJlECceumpYwAcPDiR0kRJHvNjdPq29zGM__Yw7ez9uA_DfNJGjMs4ZSI-UGfvlJu869vgBt9N9jF0Dy48WSV4KiM1Y7_eMJgT_-8g2Ml3MHhougB-Z5uxs4zagxj7KsYevm4lt69irOIvT5l6Kw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2138571455</pqid></control><display><type>article</type><title>EFFICACY OF HEAT-INACTIVATED HEPATITIS B VACCINE IN HAEMODIALYSIS PATIENTS AND STAFF: Double-blind Placebo-controlled Trial</title><source>Access via ScienceDirect (Elsevier)</source><creator>Desmyter, J. ; De Groote, G. ; Colaert, J. ; Reynders, M. ; Reerink-Brongers, E.E. ; Dees, P.J. ; Lelie, P.N. ; Reesink, H.W.</creator><creatorcontrib>Desmyter, J. ; De Groote, G. ; Colaert, J. ; Reynders, M. ; Reerink-Brongers, E.E. ; Dees, P.J. ; Lelie, P.N. ; Reesink, H.W. ; The Leuven Renal Transplantation Collaborative Group</creatorcontrib><description>The efficacy of a heat-inactivated hepatitis B vaccine, 3 μg of surface antigen (HBsAg), given at 0, 1, 2, and 5 months, was evaluated in 401 haemodialysis patients in 18 centres by a placebo-controlled, double-blind, randomised trial. The attack-rate of hepatitis B virus (HBV) infections in the control group was 18% over 435 days. The protective efficacy rate of the vaccine was 78% against all HBV infections in the entire study (p= 0·00016), and 94% against HBsAg-positive hepatitis more than 3 months after day 0. Those patients in whom HBV developed showed no evidence of vaccine-acquired anti-HBs. Among 152 similarly randomised staff members receiving three monthly injections, all 5 HBsAg-positive infections occurred in the placebo group (p=0·022). The vaccine induced anti-HBs in 88% of the patients and 100% of the staff. Immediately after the fourth injection, anti-HBs levels were as high in responding patients as in staff. There were no serious side effects. In the four-dose schedule the vaccine provides dialysis patients with protection of the same order as that given by other hepatitis B vaccines to normal subjects.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(83)91089-9</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>London: Elsevier Ltd</publisher><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Dialysis ; Effectiveness ; Emergency and intensive care: renal failure. Dialysis management ; Hemodialysis ; Hepatitis ; Hepatitis B ; Hepatitis B surface antigen ; Infections ; Intensive care medicine ; Medical sciences ; Patients ; Randomization ; Side effects ; Vaccines ; Viruses</subject><ispartof>The Lancet (British edition), 1983-12, Vol.322 (8363), p.1323-1328</ispartof><rights>1983</rights><rights>1984 INIST-CNRS</rights><rights>Copyright Elsevier Limited Dec 10, 1983</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0140-6736(83)91089-9$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=9437829$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Desmyter, J.</creatorcontrib><creatorcontrib>De Groote, G.</creatorcontrib><creatorcontrib>Colaert, J.</creatorcontrib><creatorcontrib>Reynders, M.</creatorcontrib><creatorcontrib>Reerink-Brongers, E.E.</creatorcontrib><creatorcontrib>Dees, P.J.</creatorcontrib><creatorcontrib>Lelie, P.N.</creatorcontrib><creatorcontrib>Reesink, H.W.</creatorcontrib><creatorcontrib>The Leuven Renal Transplantation Collaborative Group</creatorcontrib><title>EFFICACY OF HEAT-INACTIVATED HEPATITIS B VACCINE IN HAEMODIALYSIS PATIENTS AND STAFF: Double-blind Placebo-controlled Trial</title><title>The Lancet (British edition)</title><description>The efficacy of a heat-inactivated hepatitis B vaccine, 3 μg of surface antigen (HBsAg), given at 0, 1, 2, and 5 months, was evaluated in 401 haemodialysis patients in 18 centres by a placebo-controlled, double-blind, randomised trial. The attack-rate of hepatitis B virus (HBV) infections in the control group was 18% over 435 days. The protective efficacy rate of the vaccine was 78% against all HBV infections in the entire study (p= 0·00016), and 94% against HBsAg-positive hepatitis more than 3 months after day 0. Those patients in whom HBV developed showed no evidence of vaccine-acquired anti-HBs. Among 152 similarly randomised staff members receiving three monthly injections, all 5 HBsAg-positive infections occurred in the placebo group (p=0·022). The vaccine induced anti-HBs in 88% of the patients and 100% of the staff. Immediately after the fourth injection, anti-HBs levels were as high in responding patients as in staff. There were no serious side effects. In the four-dose schedule the vaccine provides dialysis patients with protection of the same order as that given by other hepatitis B vaccines to normal subjects.</description><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Dialysis</subject><subject>Effectiveness</subject><subject>Emergency and intensive care: renal failure. Dialysis management</subject><subject>Hemodialysis</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis B surface antigen</subject><subject>Infections</subject><subject>Intensive care medicine</subject><subject>Medical sciences</subject><subject>Patients</subject><subject>Randomization</subject><subject>Side effects</subject><subject>Vaccines</subject><subject>Viruses</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1983</creationdate><recordtype>article</recordtype><recordid>eNo9kcFq3DAQhkVpoNukj1AQJIf2oESyZFvKpaheO2vYeANWQ3MSWnkMDo6dyruFkJePNwk5Dcx8zPzMh9B3Rs8ZZclFTZmgJEl58kPyn4pRqYj6hBZMpILEIv37GS0-kC_o6zTdU0pFQuMFes6Losx0doc3BV7l2pCy0pkpb7XJl3PjRpvSlDX-jW91lpVVjssKr3R-vVmWen1Xz6MDklemxrpa4troorjEy3G_7YFs-25o8E3vPGxH4sdhF8a-hwab0Ln-BB21rp_g23s9Rn-K3GQrst5czZnWBJhkO9I61TrWyKaRwvGItxyo8pRuuWA09lHUQAxJlECceumpYwAcPDiR0kRJHvNjdPq29zGM__Yw7ez9uA_DfNJGjMs4ZSI-UGfvlJu869vgBt9N9jF0Dy48WSV4KiM1Y7_eMJgT_-8g2Ml3MHhougB-Z5uxs4zagxj7KsYevm4lt69irOIvT5l6Kw</recordid><startdate>19831210</startdate><enddate>19831210</enddate><creator>Desmyter, J.</creator><creator>De Groote, G.</creator><creator>Colaert, J.</creator><creator>Reynders, M.</creator><creator>Reerink-Brongers, E.E.</creator><creator>Dees, P.J.</creator><creator>Lelie, P.N.</creator><creator>Reesink, H.W.</creator><general>Elsevier Ltd</general><general>Lancet</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>7QL</scope><scope>7QP</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>ASE</scope><scope>C1K</scope><scope>FPQ</scope><scope>H94</scope><scope>K6X</scope><scope>K9.</scope><scope>KB~</scope><scope>M7N</scope><scope>NAPCQ</scope></search><sort><creationdate>19831210</creationdate><title>EFFICACY OF HEAT-INACTIVATED HEPATITIS B VACCINE IN HAEMODIALYSIS PATIENTS AND STAFF: Double-blind Placebo-controlled Trial</title><author>Desmyter, J. ; De Groote, G. ; Colaert, J. ; Reynders, M. ; Reerink-Brongers, E.E. ; Dees, P.J. ; Lelie, P.N. ; Reesink, H.W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e181t-fa9fa1d8dd84a323f3e09c00b34105c22de5e626e57c8c0a1ee3ecea470698353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1983</creationdate><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Dialysis</topic><topic>Effectiveness</topic><topic>Emergency and intensive care: renal failure. Dialysis management</topic><topic>Hemodialysis</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis B surface antigen</topic><topic>Infections</topic><topic>Intensive care medicine</topic><topic>Medical sciences</topic><topic>Patients</topic><topic>Randomization</topic><topic>Side effects</topic><topic>Vaccines</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Desmyter, J.</creatorcontrib><creatorcontrib>De Groote, G.</creatorcontrib><creatorcontrib>Colaert, J.</creatorcontrib><creatorcontrib>Reynders, M.</creatorcontrib><creatorcontrib>Reerink-Brongers, E.E.</creatorcontrib><creatorcontrib>Dees, P.J.</creatorcontrib><creatorcontrib>Lelie, P.N.</creatorcontrib><creatorcontrib>Reesink, H.W.</creatorcontrib><creatorcontrib>The Leuven Renal Transplantation Collaborative Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>British Nursing Index</collection><collection>Environmental Sciences and Pollution Management</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Newsstand Professional</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Desmyter, J.</au><au>De Groote, G.</au><au>Colaert, J.</au><au>Reynders, M.</au><au>Reerink-Brongers, E.E.</au><au>Dees, P.J.</au><au>Lelie, P.N.</au><au>Reesink, H.W.</au><aucorp>The Leuven Renal Transplantation Collaborative Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>EFFICACY OF HEAT-INACTIVATED HEPATITIS B VACCINE IN HAEMODIALYSIS PATIENTS AND STAFF: Double-blind Placebo-controlled Trial</atitle><jtitle>The Lancet (British edition)</jtitle><date>1983-12-10</date><risdate>1983</risdate><volume>322</volume><issue>8363</issue><spage>1323</spage><epage>1328</epage><pages>1323-1328</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><coden>LANCAO</coden><abstract>The efficacy of a heat-inactivated hepatitis B vaccine, 3 μg of surface antigen (HBsAg), given at 0, 1, 2, and 5 months, was evaluated in 401 haemodialysis patients in 18 centres by a placebo-controlled, double-blind, randomised trial. The attack-rate of hepatitis B virus (HBV) infections in the control group was 18% over 435 days. The protective efficacy rate of the vaccine was 78% against all HBV infections in the entire study (p= 0·00016), and 94% against HBsAg-positive hepatitis more than 3 months after day 0. Those patients in whom HBV developed showed no evidence of vaccine-acquired anti-HBs. Among 152 similarly randomised staff members receiving three monthly injections, all 5 HBsAg-positive infections occurred in the placebo group (p=0·022). The vaccine induced anti-HBs in 88% of the patients and 100% of the staff. Immediately after the fourth injection, anti-HBs levels were as high in responding patients as in staff. There were no serious side effects. In the four-dose schedule the vaccine provides dialysis patients with protection of the same order as that given by other hepatitis B vaccines to normal subjects.</abstract><cop>London</cop><pub>Elsevier Ltd</pub><doi>10.1016/S0140-6736(83)91089-9</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 1983-12, Vol.322 (8363), p.1323-1328 |
| issn | 0140-6736 1474-547X |
| language | eng |
| recordid | cdi_proquest_journals_2138571455 |
| source | Access via ScienceDirect (Elsevier) |
| subjects | Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Dialysis Effectiveness Emergency and intensive care: renal failure. Dialysis management Hemodialysis Hepatitis Hepatitis B Hepatitis B surface antigen Infections Intensive care medicine Medical sciences Patients Randomization Side effects Vaccines Viruses |
| title | EFFICACY OF HEAT-INACTIVATED HEPATITIS B VACCINE IN HAEMODIALYSIS PATIENTS AND STAFF: Double-blind Placebo-controlled Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T14%3A43%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=EFFICACY%20OF%20HEAT-INACTIVATED%20HEPATITIS%20B%20VACCINE%20IN%20HAEMODIALYSIS%20PATIENTS%20AND%20STAFF:%20Double-blind%20Placebo-controlled%20Trial&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Desmyter,%20J.&rft.aucorp=The%20Leuven%20Renal%20Transplantation%20Collaborative%20Group&rft.date=1983-12-10&rft.volume=322&rft.issue=8363&rft.spage=1323&rft.epage=1328&rft.pages=1323-1328&rft.issn=0140-6736&rft.eissn=1474-547X&rft.coden=LANCAO&rft_id=info:doi/10.1016/S0140-6736(83)91089-9&rft_dat=%3Cproquest_pasca%3E2138571455%3C/proquest_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2138571455&rft_id=info:pmid/&rft_els_id=S0140673683910899&rfr_iscdi=true |